Brand Institute is proud to have partnered on 46 cell and gene therapy
brand and nonproprietary (USAN/INN) names for our global clientele, including the recently FDA-approved Ryoncil from Mesoblast!
Ryoncil (remestemcel-L-rknd) was approved by the FDA on Wednesday, December 18, 2024
and is the the first-ever FDA-approved mesenchymal stromal cell (MSC) therapy.
Mesoblast
SELECT FDA-APPROVED CELL THERAPY EXPERIENCE
Iovance
Bristol-Myers Squibb
Johnson & Johnson Innovative Medicine
New York Blood Center
Orchard Therapeutics
Dendreon
BlueBird Bio
BlueBird Bio
SELECT FDA-APPROVED GENE THERAPY EXPERIENCE
Pfizer
CSL Behring
Biomarin
Novartis
Select experience listed above, not inclusive of all cell and gene therapy naming experience.
Brand Institute has been the trusted partner behind over 5,000 pharmaceutical and healthcare related brand names. Let us bring our expertise to your next branding challenge—contact us today!
